Navidea Biopharmaceuticals Inc

OTC: NAVB    
Share price (5/2/24): $0.04    
Market cap (5/2/24): $3.503 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 8-K 2 pages Second Amendment to Security Agreement
12/34/56
EX-10.3
from 8-K 3 pages Amended and Restated Secured Term Note
12/34/56
EX-10.2
from 8-K 5 pages Secured Convertible Promissory Note
12/34/56
EX-10.1
from 8-K 24 pages Navidea Biopharmaceuticals, Inc. 2023 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 2 pages July 26, 2023 Duties and Responsibilities
12/34/56
EX-10.1
from 8-K 1 page Reference Is Made to That Certain Term Note Issued to You on April 10, 2022 in the Aggregate Principal Amount of $2.5 Million. This Letter Agreement Confirms That on the Date Hereof, We Will Repay $1,073,600 Principal Amount of the Term Note by Issuing to You 12,200,000 Shares of Our Common Stock, Based on the Closing Stock Price of $0.088 Per Share on June 28, 2023. Upon Such Issuance, $1,073,600 Principal Amount of the Term Note Shall Be Cancelled and You Will Own Less Than 33.33% of Our Outstanding Common Stock. We Agree to Deliver to You a Certificate Evidencing Such Shares
12/34/56
EX-10.1
from 8-K 5 pages Second Amendment to Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 5 pages Stock Exchange Agreement
12/34/56
EX-10.2
from 8-K 6 pages Stock Purchase Agreement
12/34/56
EX-10.1
from 8-K 6 pages Stock Purchase Agreement
12/34/56
EX-10.4
from 8-K 2 pages First Amendment to Security Agreement
12/34/56
EX-10.3
from 8-K 3 pages Secured Bridge Note
12/34/56
EX-10.2
from 8-K 28 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 77 pages Common Stock Purchase Agreement Dated as of April 26, 2023 by and Among Navidea Biopharmaceuticals, Inc., and Keystone Capital Partners, LLC
12/34/56
EX-10.1
from 8-K 42 pages Asset Purchase Agreement Dated as of April 10, 2023 Between Navidea Biopharmaceuticals, Inc. a Delaware Corporation and Meilleur Technologies, Inc. a Delaware Corporation
12/34/56
EX-10.2
from 8-K 8 pages Consulting Services Agreement
12/34/56
EX-10.1
from 8-K 5 pages Separation & Release Agreement
12/34/56
EX-10.1
from S-8 16 pages Navidea Biopharmaceuticals, Inc. 2014 Stock Incentive Plan
12/34/56
EX-10.4
from 8-K 21 pages Registration Rights Agreement
12/34/56
EX-10.3
from 8-K 6 pages Security Agreement
12/34/56